Arzneiwerk VIDA 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Sascha Knoche

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	5.3yrs

최근 관리 업데이트

Recent updates

CEO

Sascha Knoche

less than a year

테뉴어

Sascha Knoche is CEO & Chairman of the Management Board of Arzneiwerk AG VIDA (formerly known as TELES Aktiengesellschaft) from January 01, 2024.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Joachim Schwarzer	Chairman of the Supervisory Board	8.1yrs	€50.00k	데이터 없음
Hartmut Brandt	Member of Supervisory Board	5.3yrs	€20.00k	데이터 없음
Markus Schmieta	Deputy Chairman of the Supervisory Board	5.3yrs	€30.00k	데이터 없음

5.3yrs

평균 재임 기간

경험이 풍부한 이사회: TLIK 의 이사회는 경험(평균 재직 기간 5.3 년)으로 간주됩니다.

Arzneiwerk VIDA 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

TELES AG Informationstechnologien, Annual General Meeting, Jul 28, 2023

TELES Aktiengesellschaft Informationstechnologien, Annual General Meeting, May 28, 2021

Recent updates

First quarter 2024 earnings released: €0.036 loss per share (vs €0.064 loss in 1Q 2023)

New minor risk - Share price stability

Full year 2023 earnings released: €0.46 loss per share (vs €0.27 loss in FY 2022)

New major risk - Share price stability

TELES Aktiengesellschaft to Report Q1, 2024 Results on May 27, 2024

Third quarter 2022 earnings released: €0.058 loss per share (vs €0.045 loss in 3Q 2021)

Third quarter 2022 earnings released: €0.038 loss per share (vs €0.045 loss in 3Q 2021)

New major risk - Market cap size

TELES AG Informationstechnologien to Report Fiscal Year 2022 Results on Aug 25, 2023

TELES AG Informationstechnologien to Report Fiscal Year 2022 Results on Jul 14, 2023

TELES AG Informationstechnologien, Annual General Meeting, Jul 28, 2023

TELES AG Informationstechnologien to Report First Half, 2023 Results on Aug 07, 2023

Second quarter 2022 earnings released: €0.037 loss per share (vs €0.001 profit in 2Q 2021)

Now 23% undervalued

Full year 2021 earnings: Revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

TELES AG Informationstechnologien (XTRA:TLIK) acquired unknown majority stake in EURO RX Arzneimittel GmbH.

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Second quarter 2021 earnings released

Investor sentiment improved over the past week

TELES AG Announces Earnings Guidance for the Year 2021

First quarter 2021 earnings released

Investor sentiment deteriorated over the past week

TELES AG Provides Earnings Guidance for the Year 2020

Investor sentiment improved over the past week

TELES Aktiengesellschaft Informationstechnologien, Annual General Meeting, May 28, 2021

Market pulls back on stock over the past week

Market pulls back on stock over the past week

Market pulls back on stock over the past week

Market bids up stock over the past week

Third quarter earnings released

New 90-day high: €1.55

New 90-day low: €1.04

New 90-day low - €1.21

TELES Aktiengesellschaft Informationstechnologien has completed a Follow-on Equity Offering in the amount of €1.514804 million.

CEO

테뉴어

이사회 구성원

평균 재임 기간